Medication - MGH Center for Women's Mental Health

Folic Acid Supplementation is Recommended for All Women Taking Anticonvulsants and Planning Pregnancy

Given recent discussions within our group and with our colleague, Lewis Holmes, MD, chief of the Genetics and Teratology Unit at Massachusetts General Hospital for Children and director of the North American AED (Antiepileptic Drug) Pregnancy Registry, I wanted to expand upon a previous blog post. In the initial post, I wrote that women who take certain medications, like mood stabilizers or antiepileptic drugs, are advised to take increased doses of folic acid before pregnancy and throughout pregnancy.

By Ruta Nonacs, MD PhD|2025-06-26T09:08:21-04:00November 11th, 2008|Anti-Epileptic Drugs, Bipolar Disorder, Medication, Mood Stabilizers, Psychiatric Disorders During Pregnancy, Treatment|Comments Off

Citalopram (Celexa) Effective for Treating Hot Flashes

For decades, estrogen has been used to treat menopausal symptoms, including night sweats and hot flushes. However, after studies reported that estrogen may have an adverse effect on risk for cardiovascular disease and breast cancer, many patients and clinicians have looked into alternative treatments for hot flashes, including selective serotonin reuptake inhibitors (SSRIs).

By MGH Center for Women's Mental Health|2015-07-28T10:34:32-04:00September 8th, 2008|Medication, Menopausal Symptoms, Treatment, Vasomotor Symptoms|Comments Off

Desvenlafaxine for the Treatment of Menopausal Hot Flushes

Last Friday, Wyeth received FDA approval for the antidepressant desvenlafaxine succinate (marketed under the name Pristiq), a metabolite of venlafaxine or Effexor. Although this drug was approved for the treatment of major depression, a recent study has demonstrated that desvenlafaxine could be an effective treatment for vasomotor symptoms in postmenopausal women.

By MGH Center for Women's Mental Health|2015-08-11T10:37:31-04:00March 7th, 2008|Medication, Menopausal Symptoms, Treatment|Comments Off

Cognitive Therapy versus Medication in the Treatment of Depression

Both antidepressant medications and cognitive therapy have been shown to be effective for the treatment of depression; however, the question remains as to whether one treatment is preferred over the other. Subjects enrolled in The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (men and women with major depression, ages 18-75) were initially treated with citalopram, an SSRI. Those who had unsatisfactory outcomes after initial treatment were eligible for a randomized second-step treatment trial in which they switched to a new treatment (either cognitive therapy or a different antidepressant) or augmented the citalopram regimen with either cognitive therapy or a different antidepressant.

By MGH Center for Women's Mental Health|2015-07-28T11:03:46-04:00November 26th, 2007|Depressive Disorders, General, Medication, Psychotherapy, Treatment|Comments Off

Duloxetine for the Treatment of Menopausal Symptoms and Mood in Postmenopausal Women

Depression is common in postmenopausal women suffering from menopausal vasomotor symptoms (hot flushes, night sweats) and insomnia. While estrogen replacement therapy may alleviate these symptoms and may also have a positive impact on mood, the use of estrogen has declined over recent years. There has been great interest in finding alternative strategies for the management of menopausal symptoms, and recent data suggest that selective serotonin reuptake inhibitor antidepressants (SSRIs) and the serotonin norepinephrine reuptake inhibitor (SNRI), venlafaxine, may be effective for the treatment of depression and vasomotor symptoms in peri- and postmenopausal women. In a study presented at the annual meeting of the American Psychiatric Association, Dr. Hadine Joffe and her colleagues at the Center of Women’s Mental Health presented data on the use of duloxetine (Cymbalta), a new SNRI, for the treatment of mood, vasomotor symptoms, and insomnia in postmenopausal women.

By MGH Center for Women's Mental Health|2015-07-28T10:00:40-04:00July 30th, 2006|Depressive Disorders, Medication, Menopausal Symptoms, Treatment, Vasomotor Symptoms|Comments Off

Escitalopram for Menopause-Related Depression and Vasomotor Symptoms

Every year more than 1.7 million women in the United States enter into menopause. During this time of hormonal fluctuations it is typical for women to experience hot flashes, night sweats and sleep disturbance. More recently, studies have identified an association between menopausal transition and an increased risk for developing depressive symptoms (Harlow et al., 2003; Freeman et al., 2004). It is not clear how physicians and patients should deal with menopause-related physical and emotional symptoms. While hormone therapy effectively treats insomnia and hot flashes, the results have been mixed in treating mood and anxiety symptoms. Moreover, the safety of long-term use of hormone therapy is not known.

By MGH Center for Women's Mental Health|2015-07-23T14:19:33-04:00December 30th, 2005|Depressive Disorders, Medication, Menopausal Symptoms, Treatment, Vasomotor Symptoms|Comments Off

Venlafaxine (Effexor) for Postmenopausal Hot Flushes

During the menopausal transition, up to 85% of women experience vasomotor symptoms of hot flushes and night sweats. For many women, hot flushes may be severe; they can interfere with work and other daily activities and affect sleep quality. Hot flushes may be associated with fatigue, poor concentration, and depression. Given the recent data from the Women's Health Initiative regarding the risks associated with long-term use of estrogen, many peri- and post-menopausal women are understandably reluctant to take menopausal hormone therapy for the treatment of hot flushes, despite its proven efficacy. Given these concerns, there is a clear need for alternative non-hormonal therapies for the treatment of hot flushes and other menopause-related symptoms.

By MGH Center for Women's Mental Health|2015-07-21T11:41:35-04:00January 18th, 2005|Medication, Menopausal Symptoms, Treatment|Comments Off

Paroxetine and Cognitive-Behavioral Therapy (CBT) for the Treatment of Postpartum Depression (PPD)

Postpartum depression (PPD) is relatively common, occurring in about 10 to 15% of women after delivery. Non-pharmacologic interventions, including interpersonal psychotherapy, have been shown to be effective for the treatment of PPD. In addition, several reports have documented the efficacy of selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitor venlafaxine (Effexor). In a recent report, Misri and colleagues have evaluated whether the addition of Cognitive-Behavioral Therapy (CBT) to standard antidepressant treatment improves outcomes in women with postpartum depression and co-morbid anxiety.

By MGH Center for Women's Mental Health|2015-07-21T11:37:31-04:00September 20th, 2004|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Psychotherapy, Treatment|Comments Off

Venlafaxine for Postpartum Depression

Postpartum depression (PPD) is relatively common, occurring in about 10 to 15% of women after delivery. Several reports have documented the efficacy of selective serotonin reuptake inhibitors (SSRIs) sertraline, fluoxetine, and fluvoxamine for the treatment of this disorder. In a recent report, Cohen and colleagues have demonstrated the efficacy of venlafaxine for the treatment of PPD.

By MGH Center for Women's Mental Health|2016-03-28T13:24:00-04:00February 20th, 2002|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off

Selecting an Antidepressant During Pregnancy

Most women and their doctors try to avoid using medications during pregnancy. Of greatest concern is that a medication used during pregnancy may in some way harm the developing fetus or, at the very worst, cause a birth defect. But what happens when a pregnant woman needs to take a medication?

By MGH Center for Women's Mental Health|2015-07-20T10:15:46-04:00May 6th, 2001|Anxiety Disorders, Child Outcomes, Depressive Disorders, Medication, Pregnancy & Medications, Psychiatric Disorders During Pregnancy, Risk of Malformations, Treatment|Comments Off